Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $20.60.
A number of research firms have weighed in on AQXP. Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 4th. Leerink Swann began coverage on shares of Aquinox Pharmaceuticals in a research note on Tuesday, October 4th. They set an “outperform” rating and a $24.00 price objective for the company. Canaccord Genuity restated a “buy” rating and set a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Finally, Jefferies Group raised their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research note on Friday, August 5th.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 10.50 on Friday. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $16.75. The stock has a 50 day moving average of $12.81 and a 200 day moving average of $9.31. The company’s market cap is $180.73 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. On average, equities research analysts expect that Aquinox Pharmaceuticals will post ($2.23) EPS for the current year.
In related news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of Aquinox Pharmaceuticals stock in a transaction dated Tuesday, September 20th. The stock was purchased at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in AQXP. Franklin Resources Inc. raised its stake in shares of Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares during the last quarter. Boxer Capital LLC increased its position in Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock worth $5,811,000 after buying an additional 57,738 shares during the last quarter. BlackRock Advisors LLC increased its position in Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock worth $2,678,000 after buying an additional 8,280 shares during the last quarter. Finally, Opaleye Management Inc. acquired a new position in Aquinox Pharmaceuticals during the second quarter worth about $1,953,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.